• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

    3/6/25 8:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email

    Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care.

    With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positively impact patient outcomes and the delivery of care through advanced technology.

    "I am excited to have Terri join the team," said Murielle Thinard McLane, President and Managing Partner at Intuitive Ventures. "She brings extensive experience as a medtech institutional investor and hands-on operator at both public companies and early-stage start-ups."

    Most recently, Burke was a Venture Partner and Head of Medtech Investments at Epidarex Capital, where she led the firm's Fund III US/UK investment strategy, deal flow and medtech brand. Burke also previously co-founded and served as CEO at Protaryx Medical, a pioneering company that enhances access and procedural efficiency in structural heart and electrophysiology interventions. Previously, she served in various senior leadership roles at Edwards Lifesciences (NYSE:EW), including Vice President of Global Marketing and Business Development where she streamlined and re-focused the heart valve business to help drive growth.

    Burke is currently a board advisor for Raydiant Oximetry, a Trustee for the Roessler-Chadwick Foundation where she also serves as Chair of the Finance Committee and member of the Executive Committee, and a Director for the Roessler-Chadwick Foundation Group.

    "Throughout my career, I've had the opportunity to position and launch products, acquire technologies and companies, fund start-up companies and raise capital for my own company – working on every side and at every stage of the entrepreneurial journey," said Burke. "I'm eager to join the team as Intuitive Ventures continues to scale its impact across the global medtech and digital health markets. I also look forward to actively collaborating with the firm's portfolio companies to support groundbreaking innovations for significant unmet clinical needs."

    In addition to the appointment of Burke, Intuitive Ventures recently welcomed Dr. Ross Jaffe as a Venture Advisor. Dr. Jaffe brings extensive experience in medical devices, diagnostics/monitoring, drug delivery, healthcare software, and venture firm management to his role advising Intuitive Ventures.

    Dr. Jaffe was one of the founders of Versant Ventures, where he remains a Legacy Managing Director, and was previously a General Partner at Brentwood Venture Capital, where he started his career as one of the first physicians in the venture capital industry. After stepping back from active investing for Versant, Dr. Jaffe also served as a Venture Advisor for New Enterprise Associates. He is currently a co-founder and Board Chair of Faro Health, an innovative clinical trial software company.

    Since its launch in 2020, Intuitive Ventures has backed 13 transformative startups working to fulfill major unmet patient needs. In 2024, the firm announced its $150 million Fund II, which is being deployed across three core areas of investment: improving healthcare access and coordination; driving precision diagnostics and interventions; and leveraging healthcare data to enhance minimally invasive care.

    About Intuitive Ventures

    Intuitive Ventures invests in companies reimagining the future of minimally invasive care. Our global focus spans diagnostics, MedTech, therapies, and digital health. With $250 million in assets under management, we back teams that share our passion for advancing positive patient outcomes, improving provider experience, and increasing the efficiency of healthcare delivery. Intuitive Ventures' experience as operators and clinicians combined with unique access to Intuitive Surgical's technical and commercial reach enables our portfolio companies to revolutionize the delivery of patient care. More information and future updates can be found at: https://ventures.intuitive.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250306137039/en/

    Media Contact

    Julie Bishop

    [email protected]

    Get the next $EW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    4/24/2025$80.00Neutral → Overweight
    Piper Sandler
    1/30/2025$75.00 → $90.00Hold → Buy
    Stifel
    1/16/2025$60.00Peer Perform → Underperform
    Wolfe Research
    12/16/2024Neutral → Buy
    BofA Securities
    10/11/2024$70.00Equal-Weight
    Morgan Stanley
    9/18/2024$85.00 → $70.00Buy → Hold
    Jefferies
    7/31/2024Neutral → Outperform
    Daiwa Securities
    7/29/2024Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Edwards Lifesciences upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00

      4/24/25 7:18:16 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences upgraded by Stifel with a new price target

      Stifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously

      1/30/25 7:10:09 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences downgraded by Wolfe Research with a new price target

      Wolfe Research downgraded Edwards Lifesciences from Peer Perform to Underperform and set a new price target of $60.00

      1/16/25 7:43:13 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Valeriani Nicholas J was granted 5,564 shares, increasing direct ownership by 8% to 79,296 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/9/25 7:58:51 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Director Sequeira Ramona was granted 3,528 shares, increasing direct ownership by 43% to 11,686 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/9/25 7:58:49 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Director Loranger Steven R was granted 4,682 shares, increasing direct ownership by 8% to 65,054 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/9/25 7:58:46 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    See more
    • Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

      Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

      3/6/25 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

      IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre

      12/8/22 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Announces Updates From Annual Meeting

      IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi

      5/5/21 9:15:00 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    SEC Filings

    See more
    • Edwards Lifesciences Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Edwards Lifesciences Corp (0001099800) (Filer)

      5/8/25 5:11:37 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Edwards Lifesciences Corporation

      10-Q - Edwards Lifesciences Corp (0001099800) (Filer)

      5/6/25 4:13:32 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form 144 filed by Edwards Lifesciences Corporation

      144 - Edwards Lifesciences Corp (0001099800) (Subject)

      5/5/25 4:03:54 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Financials

    Live finance-specific insights

    See more
    • Edwards Lifesciences Reports First Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear

      4/23/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

      Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and

      4/16/25 7:05:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences Reports Fourth Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presented results of two practice-changing FDA clinical trials, EARLY TAVR and TRISCEND II Reiterating 2025 constant currency sales growth of 8% - 10%; adjusted EPS of $2.40 - $2.50 Continuing to expect mid-year asymp

      2/11/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Edwards Lifesciences Corporation

      SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

      11/8/24 10:34:33 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

      SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

      10/4/24 2:14:28 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

      SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

      2/13/24 5:04:42 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference

      Edwards Lifesciences (NYSE:EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and p

      5/6/25 7:05:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

      Transforming Care for Severe AS Patients Edwards Lifesciences (NYSE:EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA) is based on groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance (watchful waiting). Wit

      5/1/25 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences Reports First Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear

      4/23/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/7/24 5:53:27 PM ET
      $EW
      Industrial Specialties
      Health Care